Merck & Company: Overcoming Challenges with Strategic Growth Prospects
In a report released yesterday, Evan Seigerman from BMO Capital maintained a Buy rating on Merck & Company (MRK – Research Report), ...
Merck & Company: Navigating One-Time Charges and Uncertainty in Gardasil Sales Amidst Strategic Shifts
Analyst Terence Flynn of Morgan Stanley maintained a Hold rating on Merck & Company (MRK – Research Report), reducing the price ...
manilatimes7d
Vaccinex Provides Update on ActivMAb® Platform: Multiple Project Deals and Presentation at SITC
Vaccinex has global commercial and development rights to pepinemab and is the sponsor of the KEYNOTE-B84 study which is being performed in collaboration with Merck Sharp & Dohme Corp, a subsidiary of ...
NJBIZ21d
CoreWeave clinches long-term lease, invests $1.2B at Kenilworth campus
Onyx Equities LLC and Machine Investment Group’s acquisition of the 1.7 million-square-foot former Merck ... NJ GOVERNOR’S OFFICE Karlovitch told NJBIZ that she is thrilled the Kenilworth ...
natlib.govt.nz28d
Merck manual.
About the Merck manuals. Merck & Co., Inc., Kenilworth, NJ, USA is a global healthcare leader working to help the world be well. From developing new therapies that treat and prevent disease to helping ...
UroToday28d
ASCO GU 2019: Keynote 057: Phase II trial of Pembrolizumab for Patients with High-risk NMIBC Unresponsive to BCG: Updated Interim Results
San Francisco, CA (UroToday.com) Non-muscle invasive bladder cancer (NMIBC) affects nearly 300,000 patients/year worldwide. High-risk NMIBC is defined as any carcinoma in situ, T1 tumor, and/or ...
Merck signs up to $3.3 bln cancer drug deal with China-based LaNova
Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and ...
Merck Signs up to $3.3 Billion Cancer Drug Deal With China-Based LaNova
(Reuters) -Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, ...
Merck in Cancer Licensing Pact With LaNova Medicines
Merck & Co. has struck a licensing deal with LaNova Medicines that is potentially worth more than $3 billion to the clinical-stage biotechnology company.
Joplin Globe9h
Merck to Participate in the Jefferies London Healthcare Conference
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Joseph Romanelli, president, Human Health International, and Dr. Marjorie Green, senior vice president and ...
WFMZ-TV14d
Merck is down while most of Dow Jones is up
FILE- This May 1, 2018, file photo shows Merck corporate headquarters in Kenilworth, N.J. RAHWAY, N.J. – While the Dow Jones Industrial Average has reached all-time highs recently, one of its ...
Datacenter Dynamics20d
CoreWeave to convert New Jersey lab building into data center
In the US, CoreWeave has signed leasing deals with the likes of Lincoln Rackhouse, Chirisa, Flexential, TierPoint, Digital Realty, and Core Scientific for data centers across the US, including in ...